Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for differentiated thyroid cancer in adults who have had radioactive iodine
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma (cHL) in adults
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults
Evidence-based recommendations on dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant/intolerant chronic myeloid leukaemia in adults
Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy
Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)
Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults
Evidence-based recommendations on secukinumab (Cosentyx) for ankylosing spondylitis (spondyloartritis) that has not responded well enough to conventional
Evidence-based recommendations on ramucirumab (Cyramza) for treating previously treated locally advanced or metastatic non-small-cell lung cancer
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had..
Evidence-based recommendations on bosutinib (Bosulif) for previously treated chronic myeloid leukaemia in adults
Evidence-based recommendations on interferon alfa (pegylated and non-pegylated) and ribavirin for treating chronic hepatitis C
Evidence-based recommendations on myocardial perfusion scintigraphy (MPS) for diagnosing and managing angina and myocardial infarction (MI)
Evidence-based recommendations on coronary artery stents for treating coronary artery disease (CAD)
Evidence-based recommendations on imatinib (Glivec) for treating chronic myeloid leukaemia (CML)
Evidence-based recommendations on liquid-based cytology (LBC) for cervical screening
Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humantrope, Norditropin, Saizen) in adults with growth hormone deficiency
NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE is unable to make recommendations about the use of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or…
NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for untreated..
NICE is unable to make recommendations about the use of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary…
NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating polycythaemia vera...
NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib
Evidence-based recommendations on telbivudine (Sebivo) for the treatment of chronic hepatitis B
Evidence-based recommendations on entecavir (Baraclude) for the treatment of chronic hepatitis B
Evidence-based recommendations on cetuximab (Erbitux) for the treatment of locally advanced squamous cell cancer of the head and neck
Evidence-based recommendations on rituximab (MabThera) for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism (VTE) after total hip or knee replacement in adults
Evidence-based recommendations on mifamurtide (Mepact) for treatment of osteosarcoma (bone cancer)
Evidence-based recommendations on bendamustine (Levact) for the first-line treatment of chronic lymphocytic leukaemia (CLL) of Binet stage B or C
Evidence-based recommendations on liposomal cytarabine–daunorubicin (Vyxeos) for untreated acute myeloid leukaemia (AML) in adults
Evidence-based recommendations on arsenic trioxide (Trisenox)for treating acute promyelocytic leukaemia (APML) in adults
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C (HCV) in adults
Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults
Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of overt hepatic encephalopathy
Evidence-based recommendations on secukinumab (Cosentyx) for treating moderate to severe plaque psoriasis
Evidence-based recommendations on edoxaban (Lixiana) for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism
Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation that has had inadequate response to laxatives
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Evidence-based recommendations on enzalutamide (Xtandi) for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen
Evidence-based recommendations on imatinib (Glivec) for adjuvant treatment of gastrointestinal stromal tumours (cancers in the digestive track)
Evidence-based recommendations on tocilizumab (RoActemra) for treating systemic juvenile idiopathic arthritis
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in atrial fibrillation (AF)
Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes
Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women
Evidence-based recommendations on bevacizumab (Avastin) in combination with a taxane for the first-line treatment of metastatic breast cancer
Evidence-based recommendations on aripiprazole (Abilify) for treating schizophrenia in people aged 15 to 17 years